Elliptic Laboratories Balance Sheet Health
Financial Health criteria checks 5/6
Elliptic Laboratories has a total shareholder equity of NOK313.3M and total debt of NOK1,000.0K, which brings its debt-to-equity ratio to 0.3%. Its total assets and total liabilities are NOK348.6M and NOK35.3M respectively. Elliptic Laboratories's EBIT is NOK6.1M making its interest coverage ratio 0.6. It has cash and short-term investments of NOK76.8M.
Key information
0.32%
Debt to equity ratio
NOK 1.00m
Debt
Interest coverage ratio | 0.6x |
Cash | NOK 76.78m |
Equity | NOK 313.30m |
Total liabilities | NOK 35.34m |
Total assets | NOK 348.65m |
Recent financial health updates
No updates
Recent updates
It's Unlikely That Elliptic Laboratories ASA's (OB:ELABS) CEO Will See A Huge Pay Rise This Year
May 15Elliptic Laboratories ASA's (OB:ELABS) P/S Is Still On The Mark Following 33% Share Price Bounce
May 14
Laptop And Smartphone AI Sensors Will Shape Future Markets
Expansion in the laptop and smartphone markets, with multiple AI sensors, is driving significant revenue growth and increased market penetration.Financial Position Analysis
Short Term Liabilities: ELABS's short term assets (NOK179.2M) exceed its short term liabilities (NOK24.7M).
Long Term Liabilities: ELABS's short term assets (NOK179.2M) exceed its long term liabilities (NOK10.7M).
Debt to Equity History and Analysis
Debt Level: ELABS has more cash than its total debt.
Reducing Debt: ELABS's debt to equity ratio has reduced from 63.3% to 0.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ELABS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ELABS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/06/09 08:26 |
End of Day Share Price | 2025/06/06 00:00 |
Earnings | 2025/03/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Elliptic Laboratories ASA is covered by 1 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Jørgen Weidemann | Pareto Securities |